Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Immunology
  9. Immunology Not Elsewhere Classified
  11. Resolution Of Erythema Nodosum Following Flt3-targeted Therapy In Acute Myeloid Leukemia: A Case Report.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Immunology
  9. Immunology Not Elsewhere Classified
  11. Resolution Of Erythema Nodosum Following Flt3-targeted Therapy In Acute Myeloid Leukemia: A Case Report.

Related Experiment Video

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Resolution of Erythema Nodosum Following FLT3-Targeted Therapy in Acute Myeloid Leukemia: A Case Report.

Risa Nakane1, Romane Teshima1, Natsuko Saito-Sasaki1

  • 1Dermatology, University of Occupational and Environmental Health, Kitakyushu, JPN.

Cureus
|March 17, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Erythema nodosum (EN) in a patient with acute myeloid leukemia (AML) was linked to a FLT3 mutation, a common driver in AML-M2. This highlights FLT3

Keywords:
case reporterythema nodosumflt3-itd mutationleukemia

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

Related Experiment Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

Area of Science:

  • Hematology
  • Dermatology
  • Oncology

Background:

  • Acute myeloid leukemia (AML) can present with paraneoplastic dermatological manifestations.
  • Erythema nodosum (EN) is an inflammatory condition characterized by tender subcutaneous nodules, typically on the lower legs.
  • FLT3 mutations are frequently observed in AML subtypes M2 and M4.

Observation:

  • A 59-year-old woman presented with persistent lower-leg erythema and pain, initially misdiagnosed as cellulitis.
  • The patient was diagnosed with EN and acute myeloid leukemia (AML), FAB subtype M2, harboring a FLT3-internal tandem duplication (ITD) mutation.

Findings:

  • FLT3-ITD mutations activate signaling pathways (PI3K/AKT, STAT5) that promote the production of pro-inflammatory cytokines.
  • These cytokines, including TNF-α, IL-1β, IL-6, and GM-CSF, contribute to the development of EN as a paraneoplastic phenomenon in AML.
paraneoplastic syndrome
  • The case demonstrates a direct link between FLT3 mutations in AML and inflammatory processes like EN.

    • Implications:

    • Distinguishing paraneoplastic EN from drug-induced EN is crucial for appropriate AML treatment strategies.
    • Understanding the role of FLT3 mutations in AML-associated inflammation can lead to targeted therapies.
    • This case underscores the importance of a multidisciplinary approach in diagnosing and managing complex hematologic and dermatologic conditions.